What the research found
Researchers in South Korea tested BG-104, an experimental compound that activates four distinct receptor pathways (GLP-1, GIP, growth-hormone receptors, and activin type II receptors), against tirzepatide in obese mice. When the animals lost weight on BG-104, the composition of that loss differed notably: approximately 99.5% of the weight shed came from fat tissue rather than lean mass. By comparison, the same total weight loss achieved with tirzepatide resulted in greater loss of muscle and other non-fat tissue.
The experiment used older mice that had been fed a high-fat diet for 22 weeks before treatment began. The researchers measured body composition at two timepoints during the intervention and reported that BG-104 achieved comparable overall weight reduction to tirzepatide while preserving more lean tissue. This selectivity—losing fat preferentially while sparing muscle—represents a different design goal from simply maximizing total weight loss.
Why it matters for you
If you're using GLP-1 agonists or tirzepatide for body composition, you're already aware of the muscle-loss trade-off. Most users combine peptides with resistance training and protein intake specifically to offset lean mass decline during weight loss. BG-104's apparent selectivity toward fat tissue suggests a future approach might reduce this defensive burden—you could lose adiposity without fighting as hard to retain your training gains.
The four-receptor design also touches biomarkers you likely track: growth-hormone and activin signaling influence not just fat loss but metabolic recovery and recovery capacity. If the mechanism genuinely favors fat over muscle, it might also shape your bloodwork differently than current agents—for instance, less rise in myoglobin or creatinine during a weight-loss phase. That said, this remains preclinical observation, not demonstrated clinical advantage.
Caveats
- Animal model only: findings are from aged, diet-induced obese mice, not humans; weight loss in rodents often does not scale predictably to human trials
- Abstract-only data: key methodological details are unavailable—animal numbers, sex distribution, exact age, body-composition measurement method, confidence intervals around the 99.5% figure
- No human dosing or performance data: the abstract reports tissue composition, not physical outcomes, fatigue, recovery, or adherence in people
- "Comparable" to tirzepatide is not equivalence: the statement refers to similar total weight loss under specific mouse conditions, not evidence of clinical parity or that a person switching from tirzepatide would experience the same result
- Receptor count ≠ efficacy: having four targets does not inherently confer advantage; outcomes depend on signaling direction, strength, tissue distribution, and pathway crosstalk—none of which are fully characterized here
- Early disclosure: the abstract was published June 2026 and discussed publicly in September; no peer-reviewed full paper or independent replication yet available